Status:
TERMINATED
A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
Lead Sponsor:
Eli Lilly and Company
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).
Eligibility Criteria
Inclusion
- Participants must have diagnosis of AD \>= 12 months according to the American Academy of Dermatology criteria.
- Participants must have moderate to severe AD at screening and randomization.
- Participants must have inadequate response to topical medications within 6 months of screening (or history of intolerance).
Exclusion
- Participants must not have concurrent treatment with topical or systemic treatments for AD.
Key Trial Info
Start Date :
February 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 27 2020
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT03831191
Start Date
February 12 2019
End Date
February 27 2020
Last Update
April 20 2021
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
Tien Q. Nguyen, MD inc. DBA First OC Dermatology
Fountain Valley, California, United States, 92708
2
Dermatology Research Associates
Los Angeles, California, United States, 90045
3
Quest Dermatology Research
Northridge, California, United States, 91324
4
Integrative Skin Science and Research
Sacramento, California, United States, 95815